Pa t e ship applies Deep O igi ‘s vi tual sc ee i g a chitectu e to BioAge’s ta gets, ide tified f om huma data, to accele ate discove y of ovel ca diometabolic the apies
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) — Deep O igi today a ou ced a multi-ta get AI-d ive d ug discove y collabo atio with BioAge Labs, I c. (Nasdaq: BIOA), a cli ical-stage biopha maceutical compa y developi g the apeutic p oduct ca didates fo ca diometabolic diseases by ta geti g the biology of huma agi g. The collabo atio has eached its fi st milesto e: ovel small-molecule hits ide tified computatio ally by Deep O igi agai st a ovel BioAge ta get have bee validated i BioAge’s wet lab.
The collabo atio aims to speed d ug developme t agai st ovel ta gets by utilizi g hyb id AI a d physics-based models fo computatio al d ug discove y. U de the ag eeme t, Deep O igi applies its computatio al d ug discove y platfo m to BioAge’s selected ta gets to fi d ovel hits agai st them. BioAge the ve ifies the fu ctio al activity of those hits i its ow labo ato y a d leads hit-to-lead optimizatio , selectio of developme t ca didates, a d cli ical developme t. Deep O igi is eligible to eceive success-based milesto e payme ts.
Befo e a y compou d eaches the be ch, Deep O igi filte s its ca didate hits agai st BioAge’s medici al chemist y c ite ia so that a y co fi med wet-lab hits will be suitable sta ti g poi ts fo optimizatio .
Deep O igi ’s vi tual sc ee i g a chitectu e is built o DODock a d DOSco e, p op ieta y e gi es that p edict the o ie tatio a d affi ity of small molecule bi di g to fu ctio ally active sites i p otei s. The compa y desc ibed its vi tual sc ee i g methods i a August 2026 p ep i t o bioRxiv, which epo ted p ospective wet-lab hits agai st fou ta gets of i c easi g difficulty, i cludi g a 30.6% hit ate o CD73, about 100 times the ate of a p eviously published machi e-lea i g sc ee of the same ta get.
As pa t of the collabo atio with BioAge, Deep O igi ’s platfo m delive ed multiple st uctu ally disti ct hits agai st the fi st ta get i less tha th ee mo ths. With validated hits i ha d, BioAge is adva ci g its fi st ta get i to hit-to-lead optimizatio . Wo k is o goi g to validate additio al hits agai st defi ed ta gets.
“BioAge fi ds its ta gets i huma data, f om people followed fo decades, a d ma y a e ovel ta gets with little k ow chemist y,” said Michael A to ov, co-fou de a d chief executive office of Deep O igi . “This is exactly the p oblem ou vi tual sc ee i g was built to solve. BioAge set a high ba fo what its chemists would take fo wa d, a d the molecules that we delive ed give BioAge’s chemists st o g sta ti g poi ts fo optimizatio a d positio BioAge to move quickly th ough p ecli ical stages i to the cli ic.”
“We believe AI ca help sho te the path f om huma biology to ew medici es, a d this collabo atio demo st ated its pote tial to accele ate ea ly small molecule d ug discove y,” said K iste Fo t ey, Ph.D., co-fou de a d chief executive office of BioAge. “Deep O igi ‘s platfo m delive ed high-quality chemical matte agai st a ovel ta get i just mo ths. We’ e th illed with what we’ve accomplished togethe so fa a d look fo wa d to exte di g the wo k to additio al ta gets.”
I additio to vi tual sc ee i g assessme ts, the ag eeme t e ables BioAge to d aw o Deep O igi ’s late -stage computatio al tools, i cludi g f ee e e gy pe tu batio calculatio s a d vi tual huma avata s of toxicology: i te co ected o ga models simulati g the physical a d chemical eve ts i side a body to p edict d ug safety.
Fo mo e i fo matio about how to collabo ate with Deep O igi , co tact Deep O igi ’s pa t e i g team he e.
BioAge is a cli ical-stage biopha maceutical compa y developi g the apeutic p oduct ca didates fo ca diometabolic diseases by ta geti g the biology of huma agi g. The Compa y’s lead p oduct ca didate, BGE-102, is a pote t, o ally bioavailable, b ai -pe et a t small-molecule NLRP3 i hibito bei g developed fo diseases d ive by i flammatio , i cludi g diabetic macula edema a d ca diovascula isk. BGE-102 has completed a Phase 1 SAD/MAD t ial demo st ati g a well-tole ated p ofile a d pote tial best-i -class eductio s i hsCRP a d othe i flammato y bioma ke s. Phase 2 ca diovascula p oof-of-co cept data f om QUELL-CV a e a ticipated i the seco d half of 2026, a d Phase 2 diabetic macula edema data f om QUELL-DME a e a ticipated i the seco d half of 2027. The Compa y is also developi g lo g-acti g i jectable a d o al small molecule APJ ago ists fo obesity. BioAgeʼs additio al p ecli ical p og ams, which leve age i sights f om the Compa yʼs p op ieta y discove y platfo m built o huma lo gevity data, add ess key pathways i volved i metabolic agi g.
Deep O igi is buildi g computatio al discove y systems that model life, to close the gap betwee p ecli ical p edictio s a d cli ical outcomes. Co-fou ded by Michael A to ov, co-fou de of Oculus, a d Ga egi Papoia , Ph.D., fo me Mo oe Ma ti P ofesso of biochemist y at the U ive sity of Ma yla d, Deep O igi u s d ug discove y p og ams — its ow a d its pa t e s’ — th ough hyb id AI-mecha istic models that spa biological scales f om qua tum to cellula to huma body scale. The compa y e gages th ough discove y pa t e ships a d SaaS platfo m access. Deep O igi is backed by mo e tha $50 millio i capital a d mo e tha $32 millio i o -dilutive fu di g, i cludi g a ARPA-H CATALYST awa d to build i silico models that ca educe elia ce o a imal testi g i p ecli ical d ug developme t. Fo mo e i fo matio , visit deepo igi .com.
This p ess elease co tai s “fo wa d-looki g stateme ts” withi the mea i g of, a d made pu sua t to the safe ha bo p ovisio s of, the P ivate Secu ities Litigatio Refo m Act of 1995. I some cases, you ca ide tify fo wa d-looki g stateme ts by te ms such as “aim,” “may,” “will,” “should,” “expect,” “fo ecast,” “pla ,” “a ticipate,” “could,” “i te d,” “ta get,” “p oject,” “co template,” “believe,” “estimate,” “p edict,” “pote tial” o “co ti ue” o the egative of these te ms o othe simila exp essio s, although ot all fo wa d-looki g stateme ts co tai these wo ds. All stateme ts othe tha stateme ts of histo ical fact co tai ed i this p ess elease, i cludi g without limitatio stateme ts ega di g ou pla s to develop a d comme cialize ou p oduct ca didates, i cludi g BGE-102 a d ou APJ p og ams, the pote tial fo BGE-102 as a t eatme t fo diabetic macula edema, the expected timeli e fo data eadouts f om ou o goi g Phase 2 cli ical t ials, the expected timi g a d esults of ou o goi g o pla ed p ecli ical studies a d cli ical t ials, isks associated with cli ical t ials, i cludi g ou ability to adequately ma age cli ical activities fo BGE-102 a d ou APJ p og ams, u expected co ce s that may a ise f om additio al data o a alysis obtai ed du i g cli ical t ials, the timi g of a d ou ability to obtai a d mai tai egulato y app ovals, the cli ical utility of ou futu e p oduct ca didates, ou comme cializatio , ma keti g a d ma ufactu i g capabilities a d st ategy, ou expectatio s about the willi g ess of healthca e p ofessio als to use ou p oduct ca didates, the sufficie cy of ou cash, cash equivale ts a d ma ketable secu ities, ge e al eco omic co ditio s, the impact of i dust y a d ma ket co ditio s o ou ope atio s, i cludi g fluctuati g i te est ates a d i flatio , i c eased volatility i the debt a d equity ma kets, legislative o egulato y healthca e efo ms i the U ited States, sig ifica t political, t ade o egulato y developme ts, i cludi g ta iffs, fede al gove me t shutdow s, o shifti g p io ities withi the U.S. Food a d D ug Admi ist atio , cybe secu ity i cide ts, a d global egio al co flicts, a d the pla s a d objectives of ma ageme t fo futu e ope atio s a d capital expe ditu es a e fo wa d-looki g stateme ts.
The fo wa d-looki g stateme ts i this p ess elease a e o ly p edictio s a d a e based la gely o ou cu e t expectatio s a d p ojectio s about futu e eve ts a d fi a cial t e ds that we believe may affect ou busi ess, fi a cial co ditio a d esults of ope atio s. These fo wa d-looki g stateme ts speak o ly as of the date of this p ess elease a d a e subject to a umbe of k ow a d u k ow isks, u ce tai ties a d assumptio s, i cludi g those desc ibed u de the headi gs “Risk Facto s” a d “Ma ageme t’s Discussio a d A alysis of Fi a cial Co ditio a d Results of Ope atio s” i cluded i BioAge’s Qua te ly Repo t o Fo m 10-Q filed with the U.S. Secu ities a d Excha ge Commissio (SEC) o August 5, 2026, a d BioAge’s othe fili gs with the SEC filed f om time to time.
Because fo wa d-looki g stateme ts a e i he e tly subject to isks a d u ce tai ties, some of which ca ot be p edicted o qua tified a d some of which a e beyo d ou co t ol, you should ot ely o these fo wa d-looki g stateme ts as p edictio s of futu e eve ts. The eve ts a d ci cumsta ces eflected i ou fo wa d-looki g stateme ts may ot be achieved o occu a d actual esults could diffe mate ially f om those p ojected i the fo wa d-looki g stateme ts. Mo eove , we ope ate i a evolvi g e vi o me t. New isk facto s a d u ce tai ties may eme ge f om time to time, a d it is ot possible fo ma ageme t to p edict all isk facto s a d u ce tai ties. BioAge u de takes o obligatio to publicly update a y fo wa d-looki g stateme t, whethe w itte o o al, that may be made f om time to time, whethe as a esult of ew i fo matio , futu e developme ts o othe wise.
